Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 +0.20%88 Days Payable is 28.15 as of Jun. 2026, which is 44% below its 10-year median of 50.07. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$71.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 925 Drug Manufacturers companies, TSH Biopharm ranks worse than 84.43% on this metric.
The historical data trend for TSH Biopharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Days Payable distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TSH Biopharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Days Payable of 28.15 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TSH Biopharm and its competitors. This is 44% below median its historical median of 50.07. Over the past decade, TSH Biopharm's Days Payable has ranged from 20.02 to 87.46. According to the industry distribution chart, TSH Biopharm ranks #781 out of 925 companies in the Drug Manufacturers industry, placing it in the top 84.4%.
Is TSH Biopharm's Days Payable too high?
TSH Biopharm's current Days Payable of 28.15 is 44% below median its 10-year median of 50.07. Over the past 10 years, this metric has ranged from a low of 20.02 to a high of 87.46. The Drug Manufacturers industry median Days Payable is 88.85. TSH Biopharm's value of 28.15 is 68.3% below this industry median. Based on the distribution chart, TSH Biopharm ranks #781 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #781 out of 925 companies for Days Payable. This places TSH Biopharm in the lower half of its industry. The industry median Days Payable is 88.85. TSH Biopharm's value of 28.15 is 68.3% below this benchmark. Historically, TSH Biopharm's own Days Payable has ranged from 20.02 to 87.46 over the past decade. While the company's 10-year median is 50.07 vs. the industry median of 88.85, TSH Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.85, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Days Payable of 28.15 is 68.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Days Payable is 28.15, which is 44% below median its own 10-year median of 50.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.41, compared to a current price of NT$50.80 — trading 28.9% below its estimated fair value. The current Days Payable is 28.15, which is 44% below median its 10-year median of 50.07 and 68.3% below the Drug Manufacturers industry median of 88.85. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Days Payable is 28.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.80 is trading 28.9% below its estimated GF Value™ of NT$71.41.
GuruFocus considers TSH Biopharm to be Modestly Undervalued.
Key valuation signals for ROCO:8432:
Days Payable: 28.15 (44% below median its 10-year median of 50.07)
GF Value™: NT$71.41 vs. price of NT$50.80 (28.9% below fair value)
Industry Position: 68.3% below the Drug Manufacturers median (#781 of 925)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score
Get the complete analysis for ROCO:8432
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
